Mode
Text Size
Log in / Sign up
N/A N=10 Randomized Single-blind Other

Matrix on Fruit Constituent Bioavailability

Healthy Non-smoker

Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: CMax in Polyphenol Anthocyanin Concentrations — 8.7; 22.1; 7.6; 11.3 nmol/L

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Milk-based Strawberry Beverage without meal (Dietary_supplement); Water-Based Strawberry Beverage without meal (Dietary_supplement); Milk-based strawberry Beverage with meal (Dietary_supplement); Water-Based strawberry Beverage with meal (Dietary_supplement)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
CMax in Polyphenol Anthocyanin Concentrations
8.7; 22.1; 7.6; 11.3

Summary

Primary objective is to evaluate the influence of matrix on the bioavailability of key phytochemical constituents in fruits and their subsequent effect on chronic disease risk factors.

Eligibility Criteria

Inclusion Criteria

  • Adult (18-78 years of age)
  • Relatively healthy
  • Non-smoker or past smoker with abstinence for at least 2 years

Exclusion Criteria

  • Pregnant and/or breast feeding
  • Smoker or past smoker with abstinence 2 servings per day.
  • Fasting blood glucose ≥ 126 mg/dL. Subjects identified with elevated fasting blood glucose levels will be advised to contact their primary care physician for appropriate follow-up care.
  • Taking over the counter antioxidant supplements or other supplements that may interfere with the study procedures or endpoints.
  • Subjects with unusual dietary habits (e.g. pica).
  • Actively losing weight or trying to lose weight (unstable body weight fluctuations of > 5 lbs in a 60 day period).
  • Excessive exercisers or trained athletes.
  • Subjects with documented atherosclerotic disease, inflammatory disease, diabetes mellitus, or other systemic diseases.
  • Addicted to drugs and/or alcohol.
  • Medically documented psychiatric or neurological disturbances.
  • Severe obesity as defined by >39.9 BMI or under weight for height (BMI <18.5)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01908634). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search